A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis

Background: The issue of when to start treatment in Parkinson’s disease (PD) remains controversial. Some favour treatment at diagnosis while others opt for a “wait and watch” policy. The effect of the latter policy on the self reported health status of people with PD is unknown. Aims: To record self reported health status through longitudinal use of a validated PD specific questionnaire (PDQ-39) in untreated PD patients in multiple centres in the UK. To compare patients who were left untreated with those who were offered treatment during follow-up. Methods: A multicentre, prospective, “real life” observational audit based study addressing patient reported outcomes in relation to self reported health status and other sociodemographic details. Results: 198 untreated PD were assessed over a mean period of 18 months. During two follow-up assessments, the self reported health status scores in all eight domains of the PDQ-39 and the overall PDQ-39 summary index worsened significantly (p<0.01) in patients left untreated. In a comparative group in whom treatment was initiated at or soon after diagnosis, there was a trend towards improvement in self reported health status scores after treatment was started. Conclusions: This study addresses for the first time self reported health status, an indicator of health related quality of life, in untreated PD. The findings may strengthen the call for re-evaluation of the policy to delay treatment in newly diagnosed patients with PD.

[1]  E. Lai,et al.  Non-motor Symptoms of Parkinson's Disease , 2007 .

[2]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[3]  N. MacLusky,et al.  Neurologic links between epilepsy and depression in women , 2006, Neurology.

[4]  Kallol Ray Chaudhuri,et al.  International validation of the first united non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study , 2006 .

[5]  J. Obeso,et al.  Timing of treatment initiation in Parkinson's disease: A need for reappraisal? , 2006, Annals of neurology.

[6]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[7]  M. Aminoff Treatment should not be initiated too soon in Parkinson's disease , 2006, Annals of neurology.

[8]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[9]  E. Montgomery,et al.  Slowing Parkinson’s disease progression: Recent dopamine agonist trials , 2004, Neurology.

[10]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[11]  Michael P McDermott,et al.  Development and testing of the Parkinson's disease quality of life scale , 2003, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Jankovic,et al.  Slowing Parkinson’s disease progression , 2003, Neurology.

[13]  A. Lang,et al.  Measuring motor complications in clinical trials for early Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[14]  M. Guttman,et al.  Dopamine agonist monotherapy in Parkinson's disease , 2002, The Lancet.

[15]  S. Frucht,et al.  An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines , 2002, Neurology.

[16]  R. Fitzpatrick,et al.  Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. , 2001, Age and ageing.

[17]  R M Werner,et al.  The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[18]  W. Stewart,et al.  Headache-related disability in the management of migraine , 2001, Neurology.

[19]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[20]  L. Findley,et al.  Quality of life in Parkinson's disease , 1999, International journal of clinical practice.

[21]  W. Koller,et al.  An algorithm (decision tree) for the management of Parkinson's disease , 1998, Neurology.

[22]  R. Fitzpatrick,et al.  The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.

[23]  R. Fitzpatrick,et al.  Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39) , 1995, Age and ageing.

[24]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[25]  S. Leurgans,et al.  Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS , 2005 .

[26]  Fabrizio Stocchi,et al.  Factors impacting on quality of life in Parkinson's disease: Results from an international survey , 2002, Movement disorders : official journal of the Movement Disorder Society.

[27]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[28]  H. Fukunaga,et al.  Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson's disease. , 1997, European neurology.

[29]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[30]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .